Hodgkin's disease during HIV1 infection: The French Registry Experience

• Published in: Annals of oncology Vol. 4; no. 8; pp. 635 - 641
• Main Authors: Andrieu, J. M., Roithmann, S., Tourani, J. M., Levy, R., Desablens, B., Maignan, C. le, Gastaut, J. A., Brice, P., Raphael, M., Taillan, B.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.09.1993
• Subjects: Biological and medical sciences; chemotherapy; Hematologic and hematopoietic diseases; HIV infection; Hodgkin's disease; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; radiotherapy; survival; France; Europe; Antineoplastic agent; Human; HIV-1 virus; Pathogenesis; Retroviridae; Hodgkin disease; Malignant hemopathy; Histology; Radiotherapy; Lymphoma; Survival; Infection; Virus; Concomitant disease; Chemotherapy; Treatment; Lymphoproliferative syndrome; Viral disease; Lentivirinae; Human immunodeficiency virus
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/oxfordjournals.annonc.a058617

Background: The first cases of Hodgkin's disease (HD) associated with HIV infection were reported in 1984. Since then, short series of seropositive patients suffering from HD have been published. In order to identify the characteristics, treatment response and outcome of HIV-associated Hodgkin's disease (HIV-HD), the data of HIV-HD patients recorded between 1987 and 1989 were analysed and compared with those of primary HD patient and with those of HIV-associated non-Hodgkin's lymphoma (HIV-NHL), registered during the same period. Patients and methods: The 45 cases of HD collected by the French registry of HIV-associated tumors between January 1987 and December 1989 were included in this study. All patients were clinically staged according to the Ann Arbor system. To compare HIV-HD characteristics with those of primary HD, we used a cohort of 407 patients with clinical stages (CS) LA to IVB, who were enrolled between September 1981 and August 1988 in a multicentric clinical trial. To identify the relationship between HIV-HD and the course of HIV infection we studied, when available, the routes of infection, initial CD4 cell count at the moment of HD diagnostic as well as the CDC class of HIV infection and compared these data with the same parameters observed in 142 HIV-NHL enrolled in the registry during the same period. Results: HIV-HD is characterized by an increase in mixed-cellularity histology (49%), with a predominance of advanced stages (75%) and B symptoms (80%). A unique observation is made regarding mediastinal involvement, pesent in only 13% of HIV-HD (71% in primary HD). The HIV-HD/HIV-NHL ratio was significantly higher in intravenous drug abusers than in male homosexuals. Median CD4 cell count was 306/μl at HIV-HD diagnosis, and only 11% of the cases were preceded by an AIDS manifestation. With standard therapy, 79% of the patients achieved complete remission, but hematological and infectious complications were very frequent. The progression to AIDS rate was 94% at two years and opportunistic infections were the most frequent cause of death. Overall two-year survival was 41% with 71% for patients with initial CD 4 cell counts higher than 300/μl and 0% for those with CD4 cell counts lower than 300/μl (P ± 0.01). Conclusion: HIV-HD has a particular clinico-pathological profile when compared to primary HD, with a predominance of mixed-cellularity type, a high frequency of advanced stages and a high proportion of patients without mediastinal involvement. Moreover, HIV-HD seems to occur preferentially in the group of subjects infected by needle sharing. Standard HD therapy seems to be efficient but excessively toxic.